Bedinvetmab is a canine monoclonal antibody targeting Nerve Growth Factor (NGF). The inhibition of NGF mediated cell signaling has demonstrated the ability to relieve pain associated with osteoarthritis (OA). The objective of this study was to collect long-term efficacy and safety data from client-owned dogs for the treatment of pain associated with OA in a single-arm open label study. Bedinvetmab-treated dogs previously enrolled in a three-month placebo-controlled study at veterinary practices in three EU countries were offered continued treatment (CT), provided they had responded positively based on the assessment of both the owner and veterinarian. Eighty-nine dogs received up to six additional subcutaneous monthly administrations of bedinvetmab (0.5-1.0 mg/kg). Owners assessed the dog’s pain by completing a validated Canine Brief Pain Inventory (CBPI). Treatment success was defined as a ≥1 point reduction in the Pain Severity Score and ≥2 reduction in the Pain Interference Score compared with the dog’s pre-treatment baseline. Treatment success was 48.2% (n=131) at the end of the three-month placebo-controlled study. At the beginning of the CT phase (Day 0), treatment success was 62.8% (n=78), thereafter it ranged from 73.3% to 82.2% (n=64 to 75). Eleven cases were withdrawn, ten due to developing unrelated medical conditions and one due to perceived lack of efficacy. Observed adverse events were considered typical for a population of dogs with OA and none were deemed treatment related. Results demonstrate sustained safety and efficacy of bedinvetmab after continued administration for up to nine months at a monthly minimum dose of 0.5 mg/kg.
1. Brown DC, Bell M, Rhodes L: Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. Amer J Vet Rsch 2013; 74(12):1467-1473.
2. Brown DC, Bell M, Rhodes L: ERRATUM to: Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. Amer J Vet Rsch 2014; 75(4):353.